Regulation and standards

Current tests for nephropathy may not be good enough; but research could yield new options for effective diagnosis

The views of the members of the EFLM Working Group for Preanalytical Phase

The preanalytical phase is subject to more error than any other part of the testing cycle – what can we do to improve it?

The major challenge in diagnosing the potential for breast cancer at the premalignant stages lies in recognizing it.

Although the JAMA article (1) claims to have identified a lack of consistency in pathologists’ breast cancer diagnoses, this doesn’t reflect actual clinical practice

Recent media attention on diagnostic discordance has patients shying away from cancer screening – but are they justified?

Mislabeling and contamination of cell lines in labs are well-known issues, but often nothing is done about them; journal publishers are getting tough

As consumer genetic testing becomes cheaper and easier to access, medical professionals worry that unregulated Internet marketing may steer patients in the wrong direction

New US guidelines for colorectal cancer testing highlight the importance of molecular markers

1. Do not fear social media, 2. Never post anything when angry